search
Back to results

SCS Programming Study in Treating Intractable Chronic Back Pain (NOVA) (NOVA)

Primary Purpose

Chronic Back Pain

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
DTM Programming
Conventional SCS programming
Sponsored by
SGX Nova LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Back Pain

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Be a candidate for SCS system (trial and implant) per labeled indication (back pain with or without leg pain)
  2. Have been diagnosed with chronic, refractory axial low back pain with a neuropathic component and are not eligible for spine surgery (e.g., lumbar fusion, discectomy, laminectomy, laminotomy) at the time of enrollment
  3. Has an average back pain intensity ≥ 6.0 cm on the 10.0 cm Visual Analog Scale (VAS) at the time of enrollment
  4. Be willing and capable of giving written informed consent to participate in this clinical study based on voluntary agreement after a thorough explanation of the subject's participation has been provided.
  5. Be willing and capable of subjective evaluation, read and understand written questionnaires, and read, understand and sign the written inform consent.
  6. Be 18 years of age or older at the time of enrollment
  7. Be on a stable pain medication regimen, as determined by the study investigator, for at least 30 days prior to enrolling in this study
  8. Be willing to not increase pain medications from baseline through the 3-Month Visit
  9. Be willing and able to comply with study-related requirements, procedures, and visits

Exclusion Criteria:

  1. Had previous lumbar spinal surgery (e.g., lumbar fusion, discectomy, laminectomy, laminotomy)
  2. Has a medical, anatomical, and/or psycho-social condition that is contraindicated for commercially available Intellis™ SCS systems as determined by the Investigator
  3. Has a diagnosed back condition with inflammatory causes of back pain (e.g., onset of severe pain with activity), serious spinal pathology and or neurological disorders, as determined by the Investigator
  4. Be concurrently participating in another clinical study
  5. Has an existing active implanted device such as a pacemaker, another SCS unit, peripheral nerve stimulator and/or drug delivery pump, etc.
  6. Has a pain in other area(s) and/or medical condition requiring the regular use of significant pain medications that could interfere with accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the Investigator
  7. Has mechanical spine instability as determined by the Investigator
  8. Has undergone, within 30 days prior to enrollment, an interventional procedure and/or surgery to treat back and/or leg pain, which is providing significant pain relief
  9. Has unresolved major issues of secondary gain (e.g., social, financial, legal), as determined by the investigator
  10. Be involved in an injury claim under current litigation or has a pending or approved worker's compensation claim
  11. Be pregnant (determined by urine testing unless female subject is surgically sterile or post-menopausal. If female, sexually active, and childbearing age, subject must be willing to use a reliable form of birth control.)

Sites / Locations

  • SGX Medical

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

DTM-SCS programming

Conventional SCS programming

Arm Description

This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Test treatments, which may identify the type of treatment to study participants. DTM-SCS programming has at least two programs with different pulse rate in the 50 to 1,000 Hz range and each having a maximum pulse width of 1 ms.

This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Control treatments, which may identify the type of treatment to study participants. Conventional SCS programming is stimulation parameters in the 40-250 Hz frequency range and will be trialed according to standard practice as described in the Intellis labeling/manuals

Outcomes

Primary Outcome Measures

Percentage of Subjects Who Respond to DTM-SCS Therapy Compared to Conventional SCS Therapy
The primary outcome measure is the percentage of randomized subjects (who completed the trial phase) who respond to SCS therapy at 3-months after device activation. An individual responder is a subject that experiences at least a 50% decrease in back pain relative to baseline assessment.

Secondary Outcome Measures

Full Information

First Posted
September 2, 2020
Last Updated
October 3, 2023
Sponsor
SGX Nova LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT04571242
Brief Title
SCS Programming Study in Treating Intractable Chronic Back Pain (NOVA)
Acronym
NOVA
Official Title
Open-Label, Post Market Study: Study the Effects of Differential Target Multiplexed Spinal Cord Stimulation (DTM™SCS) Programs in Treating Intractable Chronic Back Pain in Subjects Without Prior History of Spine Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Completed
Study Start Date
September 2, 2020 (Actual)
Primary Completion Date
August 17, 2022 (Actual)
Study Completion Date
April 12, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
SGX Nova LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is an open-label prospective, randomized, controlled, multi-center study comparing DTM-SCS programming approach to Conventional SCS programming approach. The purpose of this investigational study is to study the effects of Differential Target Multiplexed Spinal Cord Stimulation (DTM-SCS) in subjects with chronic, intractable pain of the trunk with or without lower limb pain, including unilateral or bilateral pain without prior history of spine surgery and refractory to conservative and surgical interventions.
Detailed Description
This is an open-label prospective, randomized, controlled, multi-center study comparing DTM-SCS programming approach to Conventional SCS programming approach. Subjects meeting study entrance criteria will be randomized in a 1:1 ratio to one of two study treatment groups: Test treatment group with DTM-SCS programming approach Control treatment group with Conventional SCS programming approach Data at follow-up visits will be compared between the two treatment groups, and in reference to baseline assessments collected at the beginning of the study. There is an optional two-way crossover to the other treatment group available for all subjects who remain implanted at 6 month visit. Up to 250 subjects may be enrolled at up to 20 clinical sites in the United States in order to include an estimated 135 subjects to the point of randomization. This would allow a minimum of 100 subjects (50% in each treatment arm) to complete the 3-month endpoint. The expected total duration of this study is approximately 32 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Back Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Subjects meeting study entrance criteria will be randomized in a 1:1 ratio to one of two study treatment groups: Test treatment group with DTM-SCS programming approach Control treatment group with Conventional SCS programming approach Data at follow-up visits will be compared between the two treatment groups, and in reference to baseline assessments collected at the beginning of the study.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
126 (Actual)

8. Arms, Groups, and Interventions

Arm Title
DTM-SCS programming
Arm Type
Active Comparator
Arm Description
This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Test treatments, which may identify the type of treatment to study participants. DTM-SCS programming has at least two programs with different pulse rate in the 50 to 1,000 Hz range and each having a maximum pulse width of 1 ms.
Arm Title
Conventional SCS programming
Arm Type
Active Comparator
Arm Description
This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Control treatments, which may identify the type of treatment to study participants. Conventional SCS programming is stimulation parameters in the 40-250 Hz frequency range and will be trialed according to standard practice as described in the Intellis labeling/manuals
Intervention Type
Device
Intervention Name(s)
DTM Programming
Intervention Description
DTM-SCS programming
Intervention Type
Device
Intervention Name(s)
Conventional SCS programming
Intervention Description
Conventional SCS programming
Primary Outcome Measure Information:
Title
Percentage of Subjects Who Respond to DTM-SCS Therapy Compared to Conventional SCS Therapy
Description
The primary outcome measure is the percentage of randomized subjects (who completed the trial phase) who respond to SCS therapy at 3-months after device activation. An individual responder is a subject that experiences at least a 50% decrease in back pain relative to baseline assessment.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be a candidate for SCS system (trial and implant) per labeled indication (back pain with or without leg pain) Have been diagnosed with chronic, refractory axial low back pain with a neuropathic component and are not eligible for spine surgery (e.g., lumbar fusion, discectomy, laminectomy, laminotomy) at the time of enrollment Has an average back pain intensity ≥ 6.0 cm on the 10.0 cm Visual Analog Scale (VAS) at the time of enrollment Be willing and capable of giving written informed consent to participate in this clinical study based on voluntary agreement after a thorough explanation of the subject's participation has been provided. Be willing and capable of subjective evaluation, read and understand written questionnaires, and read, understand and sign the written inform consent. Be 18 years of age or older at the time of enrollment Be on a stable pain medication regimen, as determined by the study investigator, for at least 30 days prior to enrolling in this study Be willing to not increase pain medications from baseline through the 3-Month Visit Be willing and able to comply with study-related requirements, procedures, and visits Exclusion Criteria: Had previous lumbar spinal surgery (e.g., lumbar fusion, discectomy, laminectomy, laminotomy) Has a medical, anatomical, and/or psycho-social condition that is contraindicated for commercially available Intellis™ SCS systems as determined by the Investigator Has a diagnosed back condition with inflammatory causes of back pain (e.g., onset of severe pain with activity), serious spinal pathology and or neurological disorders, as determined by the Investigator Be concurrently participating in another clinical study Has an existing active implanted device such as a pacemaker, another SCS unit, peripheral nerve stimulator and/or drug delivery pump, etc. Has a pain in other area(s) and/or medical condition requiring the regular use of significant pain medications that could interfere with accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the Investigator Has mechanical spine instability as determined by the Investigator Has undergone, within 30 days prior to enrollment, an interventional procedure and/or surgery to treat back and/or leg pain, which is providing significant pain relief Has unresolved major issues of secondary gain (e.g., social, financial, legal), as determined by the investigator Be involved in an injury claim under current litigation or has a pending or approved worker's compensation claim Be pregnant (determined by urine testing unless female subject is surgically sterile or post-menopausal. If female, sexually active, and childbearing age, subject must be willing to use a reliable form of birth control.)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ricardo Vallejo, MD
Organizational Affiliation
SGX Medical
Official's Role
Study Chair
Facility Information:
Facility Name
SGX Medical
City
Bloomington
State/Province
Illinois
ZIP/Postal Code
61704
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

SCS Programming Study in Treating Intractable Chronic Back Pain (NOVA)

We'll reach out to this number within 24 hrs